Actively Recruiting
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Led by Yale University · Updated on 2025-08-29
10
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
Sponsors
Y
Yale University
Lead Sponsor
N
National Institute on Drug Abuse (NIDA)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project aims to collect a densely sampled neuroimaging dataset among individuals receiving medications for opioid use disorder (MOUD). MOUD is multiphasic, comprised of medication induction, stabilization, ongoing treatment, and eventual dis-continuation phases. However, with a few small exceptions, existing neuroimaging efforts are almost exclusively single time-point assessments which, by definition, fail to capture these clinically relevant transitions and thus also do not capture individual risk and resilience trajectories. The investigators innovation, the characterization of neurocomputational trajectories during clinically relevant phases of MOUD treatment, will provide unprecedented mechanistic insight into the neurobiological basis of recovery. Once characterized, such trajectories may be used in the identification of specific therapeutic windows for additional intervention (e.g., times of increased neural plasticity) and in the design of novel tailored interventions based on known brain mechanisms (e.g., behavioral therapy, neurostimulation, neurofeedback).
CONDITIONS
Official Title
Longitudinal Neural Fingerprinting of Opioid-use Trajectories
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Within the first 6 months of methadone treatment for opioid use disorder and on a stable dose of methadone
- Eligible for MRI scanning
- Willing to commit to longitudinal study visits
You will not qualify if you...
- Current psychosis, mania, or suicidal ideation with intent
- Current severe substance-use disorders excluding nicotine and opioids
- Current intoxication or acute withdrawal preventing participation
- Severe cognitive impairment or intellectual disability
- History of neurological disease including seizures or epilepsy
- Head trauma with loss of consciousness over 30 minutes
- Organ dysfunction or unstable medical conditions affecting brain function or study participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
MRRC at The Anlyan Center
New Haven, Connecticut, United States, 06520
Actively Recruiting
Research Team
S
Sarah Yip, PhD, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
BASIC_SCIENCE
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here